Somewhat Favorable News Coverage Somewhat Unlikely to Impact Cellect Biotechnology Ltd. – American Depositary Shares (APOP) Share Price

Media headlines about Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellect Biotechnology Ltd. – American Depositary Shares earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.5866836874969 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) opened at $7.06 on Tuesday. The firm has a market capitalization of $38.41, a PE ratio of -10.54 and a beta of 5.89. Cellect Biotechnology Ltd. – American Depositary Shares has a fifty-two week low of $2.30 and a fifty-two week high of $13.50.

Several analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective (up from $12.00) on shares of Cellect Biotechnology Ltd. – American Depositary Shares in a report on Monday, September 25th. ValuEngine lowered Cellect Biotechnology Ltd. – American Depositary Shares from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Cellect Biotechnology Ltd. – American Depositary Shares (APOP) Share Price” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/12/26/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-cellect-biotechnology-ltd-american-depositary-shares-apop-share-price.html.

About Cellect Biotechnology Ltd. – American Depositary Shares

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Insider Buying and Selling by Quarter for Cellect Biotechnology Ltd. - American Depositary Shares (NASDAQ:APOP)

What are top analysts saying about Cellect Biotechnology Ltd. - American Depositary Shares? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cellect Biotechnology Ltd. - American Depositary Shares and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit